drugset
drugset / Trial / NCT00102778

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778 ↗

Phase 2 Terminated 175 enrolled ViiV Healthcare
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.

Timeline

Start
2004-12
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject APLAVIROC Small molecule — —
Background Ritonavir Other / unclassified — —

Indications

HIV infectious disease